AVEO Pharmaceuticals, Inc. (AVEO)

[ash111]

Novartis acquires global licence for AVEO Oncology's AV-380 for up to $326 million:

Novartis reached an agreement to acquire worldwide rights to AVEO Oncology's growth differentiation factor 15 inhibitor AV-380 in a deal valued at as much as $326 million, the latter drugmaker announced Monday. Under the agreed terms, Novartis will pay an upfront payment of $15 million to AVEO, which is additionally eligible to receive up to $311 million in various milestones. Shares in AVEO surged nearly 124 percent on the news.

http://www.firstwordpharma.com/node/1307581?tsid=28®ion_id=6#axzz3j6LNzAHa